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In situations like the present study, where the criteria for subject inclusion in the source trials do not exhibit much heterogeneity, this design may allow for more granular assessment of potential predictors of post-TAVR outcomes than that of a traditional meta-analysis. Despite these methodological strengths, the study design remains observational, and the analysis is potentially victim to treatment-selection bias.
The authors note several key findings. As has been seen in previous research, women were more likely to experience vascular complications and less likely to be left with post-procedural aortic insufficiency (10, 11) . The most important findings, though, related to mortality. In comparison to men, women experienced similar 30-day mortality rates but had significantly lower 1-and 2-year mortality after TAVR. applied to TAVR patients in the present study (8) .
Predicted risks between the cohorts were similar, and the actual 30-day mortalities were nearly identical. The implication is that women, despite entering the TAVR procedure with significantly fewer comorbidities than their male counterparts, sustained a similar periprocedural mortality rate as was predicted by pre-operative SAVR risk models.
However, notable differences over longer-term follow-up were seen, with women achieving higher survival rates at 1 year and mortality curves continuing to diverge to 2 years, with women increasing their survival advantage over time. From a valvular standpoint, it is well known that paravalvular aortic insufficiency was the "Achilles' heel" of the early-generation TAVR technology used in these datasets. Aortic insufficiency was less common in women because of their smaller average annular sizes and the resultant more aggressive TAVR bioprosthesis oversizing. Importantly, the authors controlled for differences in moderate or greater aortic insufficiency in their Cox proportional hazard model, ideally mitigating some of its influence on the observed results (8) . However, mild aortic insufficiency, which was also more common in men in these studies, represents a confounder, given its known relationship with late mortality (12) . Nevertheless, the differences in rates of aortic insufficiency do not seem nearly great enough to account for such significant observed mortality differences.
Apart from the issue of paravalvular aortic insufficiency, TAVR devices have proven to be quite durable technically, with late death rates largely attributed to the high burdens of comorbid conditions, both cardiac and noncardiac, present in those treated with the procedure (13, 14) . In the current study (8) , observed comorbidities were far greater in men, and attempts were made to control for these measured covariates. However, it is a distinct possibility that this widespread and significantly 
